Baird downgrades Sarepta Therapeutics stock rating on Elevidys safety concerns

Baird downgraded Sarepta Therapeutics (SRPT) to Neutral, slashing its price target to $15 from $25, citing "broad, existential uncertainty" surrounding its Duchenne muscular dystrophy treatment, Elevidys. This follows reports of an FDA request to halt Elevidys shipments, multiple patient deaths leading to an agreed black box warning, and a 25% sequential revenue decline for the drug. The downgrade, amid the stock's 80%+ decline over the past year, reflects amplified risks of Elevidys' market removal and prompts a significant 36% workforce reduction, underscoring severe regulatory and commercial challenges.

Analysis

Sarepta Therapeutics (SRPT) faces what Baird terms "broad, existential uncertainty" following a downgrade to Neutral and a price target slash to $15 from $25. This action is underpinned by severe safety and regulatory headwinds for its key Duchenne muscular dystrophy treatment, Elevidys, including reports of an impending FDA request to halt shipments and the recent death of a third gene therapy patient. The company's financial position is deteriorating, evidenced by a 25% sequential decline in preliminary Q2 revenue for Elevidys and downward earnings revisions from six analysts. In response to these pressures, which have driven the stock down over 80% in the past year, Sarepta has initiated a significant restructuring involving a 36% workforce reduction to achieve $400 million in annual cost savings. The negative sentiment is echoed across Wall Street, with BofA, BMO, Morgan Stanley, and Goldman Sachs all cutting price targets or reiterating cautious ratings, citing the patient deaths, a new black box warning for Elevidys, and amplified risk of the drug's complete market removal.

Key Decisions for Investors

• Given the confluence of severe safety events, a potential FDA-mandated halt for Elevidys, and widespread analyst downgrades, the stock's risk profile is extremely elevated, with a high probability of further capital erosion.
• Investors should prioritize monitoring official FDA communications regarding Elevidys, as the agency's decision on its market status represents the most critical near-term catalyst and a direct threat to the company's viability.
• The significant stock decline and corporate restructuring should not be mistaken for a turnaround signal; the fundamental investment thesis is broken until there is definitive positive resolution on the core regulatory and product safety crises.